Building towards a consensus for the use of tumour necrosis factor blocking agents
Open Access
- 1 December 1999
- journal article
- leader
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 58 (12), 725-726
- https://doi.org/10.1136/ard.58.12.725
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Access to disease modifying treatments for rheumatoid arthritis patientsAnnals Of The Rheumatic Diseases, 1999
- Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7Annals Of The Rheumatic Diseases, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- BIOLOGIC AGENTS AND IMMUNOTHERAPY IN RHEUMATOID ARTHRITIS: Progress and PerspectiveRheumatic Disease Clinics of North America, 1998
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.Proceedings of the National Academy of Sciences, 1992
- INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITISThe Lancet, 1989